By Victor Pikov, contributing editor
November 17, 2026 | Interstitial cystitis, or bladder pain syndrome, is a chronic condition causing persistent pelvic pain. While it shares symptoms of urinary urgency and frequency with overactive bladder in the absence of an infection, the primary differentiator is the presence of chronic pain.
While various mechanisms have been proposed, the core pathology implicates ongoing autoimmune activity, wherein the body’s immune system attacks the inner lining of the bladder. This activity is characterized by elevated levels of autoantibodies and pro-inflammatory cytokines within the bladder.
Furthermore, this autoimmune response frequently extends to surrounding organs, contributing to comorbid chronic pain conditions:
– Irritable Bowel Syndrome: Affects 30% to 50% of IC patients, marked by intestinal pain.
– Endometriosis: Affects 50% to 80% of women with IC, marked by uterine pain.
– Fibromyalgia: Affects 20% to 50% of IC patients, marked by widespread pain originating from multiple sites, including the skin, skeletal muscles, joints, tendons, heart, bladder, stomach, and intestines.
Limitations of pharmacological interventions
Current leading pharmacological treatments demonstrate minimal clinical efficacy with only a 10% to 20% modest reduction in pain scores. These interventions include:
– Intravesical platelet-rich plasma injections
– Botulinum toxin A injections
– Intravesical hyaluronic acid instillations
Clinical evidence for use of Sacral Nerve Stimulation in IC
Faced with the inadequate efficacy of drug therapies, clinicians turned to sacral nerve stimulation. SNS received FDA Premarket Approval for OAB symptoms in 1997, where it has demonstrated a 70% to 80% success rate in achieving at least a 50% reduction in daily leakage episodes. Because OAB patients do not typically experience chronic pain, the efficacy of SNS for pain management required independent evaluation specifically in IC populations.
Nearly 20 clinical studies regarding SNS use in IC have been published. The majority date from the early years of SNS therapy (1999–2011), during which surgical techniques and pain evaluation methodologies were still maturing.
Over the last decade, six studies have been published, four of which evaluated bladder pain using a standardized 1 to 10 pain scale. The key finding from these four studies (totaling 124 IC patients with an average implant duration of 2.5 years) is that the pain score dropped from values above 8 (8.1 ± 1.5) to below 4 (3.6 ± 1.7), a 45% improvement. This indicates durable, long-term efficacy that is two to three times more effective than leading pharmacological treatments.
Industry Landscape and Future Opportunities
Despite these promising clinical outcomes, all published studies have been clinician-initiated. Major SNS manufacturer—such as Medtronic and Boston Scientific (which acquired Axonics)—have not performed industry-sponsored studies for IC, despite their heavy investment in the related OAB market.
Historically, leading neuromodulation companies (Medtronic, Boston Scientific, and Abbott) have largely focused on neurological indications rather than tackling autoimmune disorders. This gap presents a significant market opportunity for emerging players in the SNS space, including Neuspera, Calm Medical, Amber Therapeutics, Uro Medical, and Juniper Biomedical, to apply SNS for durable, long-term pain relief in IC that significantly outperforms leading pharmacological interventions.



